Unlike any other equine joint product.

The only FDA-approved equine PSGAG intramuscular treatment for non-infectious degenerative joint disease (DJD) of the carpal and hock joints.

Ask your veterinarian if Adequan® i.m. (polysulfated glycosaminoglycan) is the right choice for your horse.
Healthy joints are essential.

Whether your horse is a top athlete or a treasured companion, every ride requires performance. The stress of performance increases wear and tear on joints. Wear and tear produces changes in bone and soft tissues of the joint, as well as progressive deterioration of articular cartilage, which are hallmarks of degenerative joint disease (DJD).¹

DJD can occur within any joint that consistently experiences wear and tear. Over time, DJD causes lameness, which may be noticeable by an owner, rider, trainer or veterinarian. DJD is a common problem that affects career longevity of performance horses, regardless of discipline. For most horses, it’s not if DJD will occur, but when.¹

What is degenerative joint disease (DJD)?

Equine DJD, commonly referred to as osteoarthritis (or OA) can cause lameness in horses of all breeds and ages. This painful disease is characterized by progressive deterioration of the articular cartilage, which is accompanied by changes in bone and soft tissues of the joint.¹

**INDICATIONS** Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Start early to help your horse keep moving and performing.

Since joint damage can escalate, it’s important to diagnose DJD early and minimize progression of the disease. Many products are available to help reduce pain and inflammation or improve mobility, including NSAIDs and supplements. But there’s only one PSGAG treatment that proactively treats the disease and not just the signs of DJD.2

The only FDA-approved equine PSGAG that actually treats the disease and not just the signs of DJD.

Adequan® i.m. (polysulfated glycosaminoglycan) not only reaches joints quickly, but also helps to protect and renew joint mobility. After 30 years, it’s still the only FDA-approved equine PSGAG intramuscular treatment for non-infectious DJD of the carpal and hock joints proven to:2,3

- Reduce inflammation
- Restore synovial joint lubrication
- Repair joint cartilage
- Reverse the disease process

The benefits of adhering to the labeled dosing regimen:

Over 50% improvement in maximum carpal flexion.4

The benefits of 1•4•7 dosing.

Based on findings in a Dose Response Study4 the recommended optimal dosage of Adequan® i.m.

Administer 1 (500 mg) dose Every 4 days For 7 treatments

Restricted to use by or on the order of a licensed veterinarian.

INDICATIONS Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. IMPORTANT SAFETY INFORMATION There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Please see accompanying Full Prescribing Information or visit adequan.com.
Reasons why veterinarians start with it and stay with it.

- **Reliable** — the only FDA-approved equine intramuscular polysulfated glycosaminoglycan
- **Proven** — backed by efficacy and safety studies reviewed by the FDA
- **Trusted** — millions of doses administered to equine patients

Adequan® is truly an icon in equine joint treatment. That’s why many veterinarians recommend it.

“Diagnosing horses with degenerative joint disease earlier is when we have the opportunity to make a difference. For us, a product that has great ease of i.m. administration and FDA approval behind it is an easy choice.”

— Kelly B. Tisher, DVM
Littleton Equine Medical Center

Start with it. Stay with it:

Adequan® i.m. polysulfated glycosaminoglycan

For Intramuscular Use In Horses

**CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**DESCRIPTION:** Each 5 milliliters of Adequan® i.m. contains 500 mg of Polysulfated Glycosaminoglycan (PSGAG) and Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid added when necessary to adjust pH. Sodium Chloride may be added to adjust tonicity.

**PHARMACOLOGY:** Polysulfated Glycosaminoglycan is chemically similar to the glycosaminoglycans in articular cartilage matrix. PSGAG is a potent proteolytic enzyme inhibitor and diminishes or reverses the pathologic processes of traumatic or degenerative joint disease which result in a net loss of cartilage matrix components. PSGAG improves joint function by reducing synovial fluid protein levels and increasing synovial fluid hyaluronic acid concentration in traumatized equine carpal and hock joints.

**INDICATIONS:** Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

**DOSAGE AND ADMINISTRATION:** The recommended dose of Adequan® i.m. in horses is 500 mg every 4 days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan® i.m. with other drugs or solvents.

**CONTRAINdications:** There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan.

**WARNINGS:** Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children.

**PRECAUTIONS:** The safe use of Adequan® i.m. in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated.

**ANIMAL SAFETY:** Toxicity studies were conducted in horses. Doses as high as 2,500 mg were administered intramuscularly to 6 horses twice a week for 12 weeks. This dosage is 5 times the recommended dosage and 3 times the recommended therapeutic regimen. Clinical observations revealed no soreness or swelling at the injection site or in the affected joint. No animal had any clinical or laboratory evidence of toxicity.

**STORAGE CONDITIONS:** Store at 20°-25°C (68°-77°F); (See USP Controlled Room Temperature). Discard unused portion.

**HOW SUPPLIED:** Adequan® i.m. solution, 500 mg/5 mL (100 mg/mL) in a 5 mL single dose glass vial.

NDC 10797-995-70 5 mL Single Dose Vials Packaged 7 vials per box

**AMERICAN REGENT, INC.**

Shirley, NY 11967
(1-888-354-4857)

Approved by FDA under NADA # 140-901

Approved by FDA under NADA # 140-901